Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Hoeper, R. Barst, N. Galie, P. Hassoun, N. Morrell, A. Peacock, G. Simonneau, V. Tapson, F. Torres, D. Lawrence, D. Quinn, H.A. Ghofrani (Hanover, Giessen, Germany; New York, Baltimore, Durham, Dallas, Cambridge, United States Of America; Bologna, Italy; Cambridge, Glasgow, Horsham, United Kingdom; Orsay, France). Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Eur Respir J 2012; 40: Suppl. 56, 3270

Member's Comments

No comment yet.

Related content which might interest you: Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Initial dual oral combination therapy in pulmonary arterial hypertension Source: Eur Respir J 2016; 47:1727-1736 Year: 2016 Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension Source: Eur Respir J 2010; 36: 808-818 Year: 2010 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013